Navigation Links
Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
Date:1/4/2012

iliary artery. Vision loss resulting from NAION is typically sudden and painless, and in most cases patients have permanent visual deficits. There are no approved therapies available for these patients.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc., is a clinical-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. The Company has a fully integrated drug development platform that spans therapeutic target identification based on its proprietary gene discovery technology, to clinical drug development. Quark has three product candidates in clinical development in five different disease indications of which four are in Phase 2. QPI-1007, a chemically modified synthetic siRNA, is Quark's first drug candidate based on novel siRNA structures developed though an internal program conducted by Quark in collaboration with BioSpring AG.

Quark is committed to leveraging a broad research pipeline of siRNA drug candidates and novel siRNA structures to develop additional RNAi drug candidates.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at www.quarkpharma.com.

(1) The Ischemic Optic Neuropathy Decompression Trial Research Group (1995). Optic Nerve Decompression Surgery for Nonarteritic Anteriror Ischemic Optic Neuropathy (NAION) is Not Effective and May Be Harmful. JAMA, Vol.273, pp.625 – 632; and (2) Hayreh S.S. & Zimmerman M.B. (2008). Non-arteritic Anterior Ischemic Optic Neuropathy. Natural History of Visual Outcome. J. Ophthalmology, pp.298-305.

 

'/>"/>

Quark Pharmaceuticals, Inc.

Juliana Friedman

+972 89 30 5111

jfriedman@quarkpharma.com

 

 


SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Most osteoporosis patients want a choice ... online survey* sponsored by Mission Pharmacal Company. The survey, ... Foundation online support community, revealed that 74 percent of ... in a form other than a pill or a ...
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Md., June 01, 2007 /PRNewswire-FirstCall/ --,EntreMed, Inc. ... the treatment of cancer and inflammatory diseases,announced ... Aurora,kinase - angiogenesis inhibitor, ENMD-981693. The data ... EntreMed,scientists at the 2nd Protein Kinases in ...
... Calif., June 01, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. ... ongoing clinical,studies of SNS-595 and SNS-032 at the ... held June 7-10, 2007 in Vienna,Austria. , Presentations ... 1 clinical trial of SNS-595 in acute leukemias, ...
Cached Medicine Technology:EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models 2EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models 3Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 2Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 3
(Date:7/11/2014)... 11, 2014 Shoulder instability is a ... return to play has not been regularly determined following ... Society for Sports Medicine’s ( AOSSM ) Annual Meeting ... approximately 90 percent no matter what the stabilization procedure ... rate of return to play following shoulder stabilization surgery. ...
(Date:7/11/2014)... occur more than 200,000 times a year, but the ... may determine how long you stay in the game, ... Meeting of the American Orthopaedic Society of Sports Medicine ... in a young athletic population, allografts (tissue harvested from ... harvested from the patient)," said Craig R. Bottoni, MD, ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Woodland Hills ... founder of the Anacapa Dental Art Institute in Woodland Hills ... Biocare World Symposium in Marina Del Rey, Calif. , ... master class on the permanent teeth in one day dental ... teeth in one day was developed 15 years ago, Dr. ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The World Cup ... according to recent reports , many star soccer players left ... in the media to American football when it comes to ... risk is always there. While none of the soccer superstars ... possibility remains. Beverly Hills spine surgeon Dr. Gravori reveals some ...
(Date:7/11/2014)... 2014 On Tuesday, July 9, Eric ... VA office joined CBS affiliate WUSA’s Andrea Roane ... the audience about the number of ways Shady Grove ... motherhood possible for women after they undergo cancer ... patients in the developing field known as oncofertility which ...
Breaking Medicine News(10 mins):Health News:Stabilizing Shoulder Surgery Helps NFL Players Return to the Game 2Health News:ACL reconstructions may last longer with autografts 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 3Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 4Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 5Health News:As World Cup Comes to an End, Injuries are Star of the Show 2Health News:As World Cup Comes to an End, Injuries are Star of the Show 3Health News:Baby After Cancer Is a Reality as Shady Grove Fertility Provides Successful Treatment for Cancer Survivors 2Health News:Baby After Cancer Is a Reality as Shady Grove Fertility Provides Successful Treatment for Cancer Survivors 3Health News:Baby After Cancer Is a Reality as Shady Grove Fertility Provides Successful Treatment for Cancer Survivors 4
... The University of Houston (UH) will soon open its doors ... a new joint venture between the UH Graduate College of ... Cancer Center Division of Cancer Prevention and Population Sciences. CHEER ... the newly opened center at UH GCSW. CHEER ...
... blood vitamin D levels, there,s uncertainty about where the ... threshold amount has become controversial as several scientific societies ... University of Washington researchers conducted an observational study. They ... circulating in the blood to lower the risk of ...
... , TUESDAY, May 1 (HealthDay News) -- Children with ... hospitalized than children without arthritis, a new study says. ... higher infection risk among kids with arthritis, other arthritis ... inhibitors -- were not. Researchers analyzed Medicaid ...
... can have as much effect on the teens, substance ... "Among friendship groups with ,good parents, there,s a ... aware of your whereabouts, and your friends, parents are ... you are less likely to use substances," said Michael ...
... announced today the inaugural class of its Presidential ... early career researchers with financial support to attend ... exclusive networking and mentoring opportunities with AcademyHealth leadership ... "The presidential scholarships are an opportunity for ...
... 1, 2012 Scientists at Joslin Diabetes Center have identified ... rapamycin) protein kinase, a critical regulator of cell growth which ... finding not only illuminates the physiology of aging but could ... conditions, such as cancer, type 2 diabetes, and neurodegeneration. ...
Cached Medicine News:Health News:University of Houston Graduate College of Social Work announces partnership with MD Anderson 2Health News:Researchers determine vitamin D blood level for reducing major medical risks in older adults 2Health News:Arthritis in Children Linked to Infections 2Health News:It takes a village to keep teens substance free 2Health News:First recipients of AcademyHealth's Presidential Scholarship announced 2Health News:Joslin scientists identify important mechanism that affects the aging process 2Health News:Joslin scientists identify important mechanism that affects the aging process 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: